EMEA-002869-PIP03-21
Key facts
| Active substance |
Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0141/2022
|
| PIP number |
EMEA-002869-PIP03-21
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of zoonotic influenza
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
Seqirus Netherlands B.V.
E-mail: seqirus.clinicaltrials@seqirus.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-002869-PIP03-21
|
| Compliance opinion date |
09/09/2022
|
| Compliance outcome |
positive
|